Sanofi Appoints Paulo Fontoura as Global Head of Pharmaceutical R&D
Following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi, Paulo Fontoura announced his resignation from the board of directors of Lakefront Biotherapeutics on July 13.
A Major Appointment at the French Pharmaceutical Giant
Paulo Fontoura resigned following his promotion to Executive Vice President, Global Head of Pharmaceutical Research and Development at Sanofi. This appointment entrusts him with the global responsibility for the research and development of the French group's pharmaceutical division, occurring at a time when Sanofi is bolstering its clinical portfolio with several significant regulatory advancements.
Ongoing Succession at Lakefront
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Gino Santini, chairman of the board at Lakefront, praised the appointment and thanked Fontoura for his contributions during his tenure. The biotech company is committed to appointing a successor on the board at the earliest practical opportunity.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 2025
Key reported figures
Revenue: 43 626 millions d'euros
Revenue growth: 9,9 %
Net income: 9 555 millions d'euros
Free cash flow: 8 089 millions d'euros
11 008 millions d'euros
Dividend per share: 4,12 €
Outlook / guidance
Expected revenue: Le chiffre d'affaires 2026 devrait croître à un chiffre élevé à taux de change constants.
Management commentary: Pour 2026, Sanofi anticipe une croissance solide et rentable et prévoit un programme de rachat d'actions d'un montant d'un milliard d'euros en 2026; un dividende de 4,12 euros est proposé.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
